Document Detail


Targeting the HGF/Met signaling pathway in cancer therapy.
MedLine Citation:
PMID:  22530990     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Under normal conditions, hepatocyte growth factor (HGF)-induced activation of its cell surface receptor, the Met tyrosine kinase (TK), is tightly regulated by paracrine ligand delivery, ligand activation at the target cell surface, and ligand-activated receptor internalization and degradation. Despite these controls, HGF/Met signaling contributes to oncogenesis and tumor progression in several cancers and promotes aggressive cellular invasiveness that is strongly linked to tumor metastasis.
AREA COVERED: The prevalence of HGF/Met pathway activation in human malignancies has driven rapid growth in cancer drug development programs. The authors review Met structure and function, the basic properties of HGF/Met pathway antagonists now in preclinical and clinical development, as well as the latest clinical trial results.
EXPERT OPINION: Clinical trials with HGF/Met pathway antagonists show that as a class these agents are well tolerated. Although widespread efficacy was not seen in several completed Phase II studies, promising results have been reported in lung, gastric, prostate and papillary renal cancer patients treated with these agents. The main challenges facing the effective use of HGF/Met-targeted antagonists for cancer treatment are optimal patient selection, diagnostic and pharmacodynamic biomarker development, and the identification and testing of optimal therapy combinations. The wealth of basic information, analytical reagents, and model systems available concerning HGF/Met oncogenic signaling will continue to be invaluable in meeting these challenges and moving expeditiously toward more effective disease control.
Authors:
Fabiola Cecchi; Danie C Rabe; Donald P Bottaro
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural; Review     Date:  2012-04-25
Journal Detail:
Title:  Expert opinion on therapeutic targets     Volume:  16     ISSN:  1744-7631     ISO Abbreviation:  Expert Opin. Ther. Targets     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-05-16     Completed Date:  2012-09-04     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101127833     Medline TA:  Expert Opin Ther Targets     Country:  England    
Other Details:
Languages:  eng     Pagination:  553-72     Citation Subset:  IM    
Affiliation:
National Cancer Institute, National Institutes of Health, Center for Cancer Research, Urologic Oncology Branch, 10 Center Drive MSC 1107, Bethesda, MD 20892-1107, USA. cecchif@mail.nih.gov
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents / therapeutic use
Hepatocyte Growth Factor / antagonists & inhibitors,  metabolism*
Humans
Neoplasms / drug therapy,  metabolism*
Proto-Oncogene Proteins c-met / antagonists & inhibitors,  metabolism*
Signal Transduction
Grant Support
ID/Acronym/Agency:
Z01 BC011124-01/BC/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 67256-21-7/Hepatocyte Growth Factor; EC 2.7.10.1/Proto-Oncogene Proteins c-met
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparing the mitochondrial genomes of Wolbachia-dependent and independent filarial nematode species...
Next Document:  Feeding guild structure of beetles on Australian tropical rainforest trees reflects microhabitat res...